[HTML][HTML] Thrombosis and hyperinflammation in COVID-19 acute phase are related to anti-phosphatidylserine and anti-phosphatidylinositol antibody positivity
J Alijotas-Reig, A Anunciación-Llunell… - Biomedicines, 2023 - mdpi.com
J Alijotas-Reig, A Anunciación-Llunell, S Morales-Pérez, J Trapé, E Esteve-Valverde…
Biomedicines, 2023•mdpi.comAntiphospholipid antibodies (APLA) are strongly associated with thrombosis seen in patients
with antiphospholipid syndrome. In COVID-19, thrombosis has been observed as one of the
main comorbidities. In patients hospitalised for COVID-19, we want to check whether APLA
positivity is associated with COVID-19-related thrombosis, inflammation, severity of disease,
or long COVID-19. We enrolled 92 hospitalised patients with COVID-19 between March and
April 2020 who were tested for 18 different APLAs (IgG and IgM) with a single line …
with antiphospholipid syndrome. In COVID-19, thrombosis has been observed as one of the
main comorbidities. In patients hospitalised for COVID-19, we want to check whether APLA
positivity is associated with COVID-19-related thrombosis, inflammation, severity of disease,
or long COVID-19. We enrolled 92 hospitalised patients with COVID-19 between March and
April 2020 who were tested for 18 different APLAs (IgG and IgM) with a single line …
Antiphospholipid antibodies (APLA) are strongly associated with thrombosis seen in patients with antiphospholipid syndrome. In COVID-19, thrombosis has been observed as one of the main comorbidities. In patients hospitalised for COVID-19, we want to check whether APLA positivity is associated with COVID-19-related thrombosis, inflammation, severity of disease, or long COVID-19. We enrolled 92 hospitalised patients with COVID-19 between March and April 2020 who were tested for 18 different APLAs (IgG and IgM) with a single line-immunoassay test. A total of 30 healthy blood donors were used to set the cut-off for each APLA positivity. Of the 92 COVID-19 inpatients, 30 (32.61%; 95% CI [23.41–43.29]) tested positive for APLA, of whom 10 (33.3%; 95% CI [17.94–52.86]) had more than one APLA positivity. Anti-phosphatidylserine IgM positivity was described in 5.4% of inpatients (n = 5) and was associated with the occurrence of COVID-19-related thrombosis (p = 0.046). Anti-cardiolipin IgM positivity was the most prevalent among the inpatients (n = 12, 13.0%) and was associated with a recorded thrombosis in their clinical history (p = 0.044); however, its positivity was not associated with the occurrence of thrombosis during their hospitalisation for COVID-19. Anti-phosphatidylinositol IgM positivity, with a prevalence of 5.4% (n = 5), was associated with higher levels of interleukin (IL)-6 (p = 0.007) and ferritin (p = 0.034). Neither of these APLA positivities was a risk factor for COVID-19 severity or a predictive marker for long COVID-19. In conclusion, almost a third of COVID-19 inpatients tested positive for at least one APLA. Anti-phosphatidylserine positivity in IgM class was associated with thrombosis, and anti-phosphatidylinositol positivity in IgM class was associated with inflammation, as noticed by elevated levels of IL-6. Thus, testing for non-criteria APLA to assess the risk of clinical complications in hospitalised COVID-19 patients might be beneficial. However, they were not related to disease severity or long COVID-19.
MDPI